Aadi Bioscience, AMPECT, Fyarro, metastatic malignant PEComa, PEComa, RECIST
Sirolimus protein-bound particles is approved for malignant perivascular epithelioid cell tumor
Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug Administration licenced sirolimus protein-bound particles for injectable suspension ..
Jemperli, platinum-containing regimen, RECIST
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, a..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RECIST, USFDA
Pembrolizumab is approved by FDA for adjuvant treatment of melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..